company background image

Cipla Quality Chemical Industries UGSE:CQCIL Stock Report

Last Price


Market Cap







27 Sep, 2022


Company Financials
CQCIL fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health4/6

CQCIL Stock Overview

Cipla Quality Chemical Industries Limited, a pharmaceutical manufacturing company, manufactures and delivers anti-retroviral, anti-malarial, and hepatitis B medicines.

Cipla Quality Chemical Industries Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cipla Quality Chemical Industries
Historical stock prices
Current Share PriceUSh65.00
52 Week HighUSh100.00
52 Week LowUSh65.00
1 Month Change-7.14%
3 Month Change-5.80%
1 Year Change-31.58%
3 Year Change-49.22%
5 Year Changen/a
Change since IPO-75.19%

Recent News & Updates

Shareholder Returns

CQCILUG PharmaceuticalsUG Market

Return vs Industry: CQCIL exceeded the UG Pharmaceuticals industry which returned -34.6% over the past year.

Return vs Market: CQCIL underperformed the UG Market which returned -29% over the past year.

Price Volatility

Is CQCIL's price volatile compared to industry and market?
CQCIL volatility
CQCIL Average Weekly Movement2.1%
Pharmaceuticals Industry Average Movement4.1%
Market Average Movement3.2%
10% most volatile stocks in UG Market4.5%
10% least volatile stocks in UG Market1.1%

Stable Share Price: CQCIL is less volatile than 75% of UG stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: CQCIL's weekly volatility (2%) has been stable over the past year.

About the Company

2005n/aAjay Pal

Cipla Quality Chemical Industries Limited, a pharmaceutical manufacturing company, manufactures and delivers anti-retroviral, anti-malarial, and hepatitis B medicines. It offers Duovir-N; Lamivudine and Zidovudine; Efavir 60; Duomune; Nevirapine; Efavirenz, Lamivudine, and Tenofovir; and Dolutegravir, Lamivudine, and Tenofovir tablets for the treatment of HIV infection. The company also offers Lumartem/Lumet tablets for the treatment of malaria; and Texavir and Zentair for the treatment of Hepatitis B infection.

Cipla Quality Chemical Industries Fundamentals Summary

How do Cipla Quality Chemical Industries's earnings and revenue compare to its market cap?
CQCIL fundamental statistics
Market CapUSh237.37b
Earnings (TTM)-USh10.54b
Revenue (TTM)USh284.54b


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CQCIL income statement (TTM)
Cost of RevenueUSh229.51b
Gross ProfitUSh55.03b
Other ExpensesUSh65.56b

Last Reported Earnings

Mar 31, 2021

Next Earnings Date


Earnings per share (EPS)-2.89
Gross Margin19.34%
Net Profit Margin-3.70%
Debt/Equity Ratio25.5%

How did CQCIL perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is CQCIL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CQCIL?

Other financial metrics that can be useful for relative valuation.

CQCIL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.9x
Enterprise Value/EBITDA22.4x
PEG Ration/a

Price to Sales Ratio vs Peers

How does CQCIL's PS Ratio compare to its peers?

CQCIL PS Ratio vs Peers
The above table shows the PS ratio for CQCIL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average3x
CAN Cann Group
503 Lansen Pharmaceutical Holdings
APPH Apontis Pharma
A041910 EstechPharma
CQCIL Cipla Quality Chemical Industries

Price-To-Sales vs Peers: CQCIL is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (3x).

Price to Earnings Ratio vs Industry

How does CQCIL's PE Ratio compare vs other companies in the African Pharmaceuticals Industry?

Price-To-Sales vs Industry: CQCIL is good value based on its Price-To-Sales Ratio (0.8x) compared to the African Pharmaceuticals industry average (0.8x)

Price to Sales Ratio vs Fair Ratio

What is CQCIL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CQCIL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate CQCIL's Price-To-Sales Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of CQCIL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CQCIL (UGX65) is trading above our estimate of fair value (UGX41.71)

Significantly Below Fair Value: CQCIL is trading above our estimate of fair value.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Cipla Quality Chemical Industries forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cipla Quality Chemical Industries has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

Past Performance

How has Cipla Quality Chemical Industries performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Last years earnings growth

Earnings and Revenue History

Quality Earnings: CQCIL is currently unprofitable.

Growing Profit Margin: CQCIL is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if CQCIL's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare CQCIL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CQCIL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (30.7%).

Return on Equity

High ROE: CQCIL has a negative Return on Equity (-7.77%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Cipla Quality Chemical Industries's financial position?

Financial Health Score


Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: CQCIL's short term assets (UGX143.9B) exceed its short term liabilities (UGX65.8B).

Long Term Liabilities: CQCIL's short term assets (UGX143.9B) exceed its long term liabilities (UGX24.7B).

Debt to Equity History and Analysis

Debt Level: CQCIL's net debt to equity ratio (18.8%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if CQCIL's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: CQCIL's debt is well covered by operating cash flow (79.5%).

Interest Coverage: CQCIL's interest payments on its debt are not well covered by EBIT (1.5x coverage).

Balance Sheet

Discover healthy companies


What is Cipla Quality Chemical Industries's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Cipla Quality Chemical Industries Dividend Yield vs Market
How does Cipla Quality Chemical Industries dividend yield compare to the market?
SegmentDividend Yield
Company (Cipla Quality Chemical Industries)0%
Market Bottom 25% (UG)5.6%
Market Top 25% (UG)10.9%
Industry Average (Pharmaceuticals)2.5%
Analyst forecast in 3 Years (Cipla Quality Chemical Industries)n/a

Notable Dividend: Unable to evaluate CQCIL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CQCIL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CQCIL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CQCIL's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: CQCIL is not paying a notable dividend for the UG market.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CQCIL has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Ajay Pal



Ajay Kumar Pal serves as Chief Executive Officer since February 2020 & Executive Director at Cipla Quality Chemical Industries Limited. Ajay Kumar Pal joined CiplaQCIL in February 2020.

Leadership Team

Experienced Management: CQCIL's management team is seasoned and experienced (13.7 years average tenure).

Board Members

Experienced Board: CQCIL's board of directors are considered experienced (4.1 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of CQCIL?
Owner TypeNumber of SharesOwnership Percentage
General Public64,023,1001.8%
Individual Insiders309,799,1268.5%
VC/PE Firms407,152,19111.1%
Private Companies420,402,71311.5%
Public Companies1,869,170,68451.2%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 9 shareholders own 98.25% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
Cipla Limited
1,869,170,684UGX121.5b0%no data
amistad Limited
420,402,713UGX27.3b0%no data
Capitalworks SSA 1
407,152,191UGX26.5b0%no data
Public Investment Corporation Limited
National Social Security Fund
George Baguma
101,933,042UGX6.6b0%no data
Emmanuel Katongole
101,933,042UGX6.6b0%no data
Frederick Kitaka
101,933,042UGX6.6b0%no data
Joseph Yiga
4,000,000UGX260.0m0%no data

Company Information

Cipla Quality Chemical Industries Limited's employee growth, exchange listings and data sources

Key Information

  • Name: Cipla Quality Chemical Industries Limited
  • Ticker: CQCIL
  • Exchange: UGSE
  • Founded: 2005
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: USh237.374b
  • Shares outstanding: 3.65b
  • Website:

Number of Employees


  • Cipla Quality Chemical Industries Limited
  • Luzira Industrial Park
  • Plot 1-7, 1st Ring Road
  • Kampala
  • Uganda


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CQCILUGSE (Uganda Stock Exchange)YesOrdinary SharesUGUGXSep 2018

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/27 00:00
End of Day Share Price2022/09/27 00:00
Annual Earnings2021/03/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.